$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

$vtgn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000141168524000048 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$200.0K	$277.7K
YoY Change		-27.98%	-131.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.195M	$3.210M
YoY Change		30.69%	-13.3%
% of Gross Profit
Research & Development		$10.22M	$3.851M
YoY Change		165.28%	-70.14%
% of Gross Profit
Depreciation & Amortization		$37.00K	$30.00K
YoY Change		23.33%	-9.91%
% of Gross Profit
Operating Expenses		$14.41M	$7.058M
YoY Change		104.17%	-57.47%
Operating Profit		-$14.23M	-$6.780M
YoY Change		109.83%	-61.23%
Interest Expense		$1.273M	$190.0K
YoY Change		570.0%	3014.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$12.95M	-$6.588M
YoY Change		96.64%	-62.32%
Income Tax		$7.000K	$0.00
% Of Pretax Income
Net Earnings		-$12.96M	-$6.588M
YoY Change		96.75%	-62.32%
Net Earnings / Revenue		-6480.5%	-2372.24%
Basic Earnings Per Share		-$0.42	-$0.66
Diluted Earnings Per Share		-$0.42	-$0.66
COMMON SHARES
Basic Shares Outstanding	27.84M shares	27.06M shares	9.362M
Diluted Shares Outstanding		30.63M shares	10.04M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.58M	$37.60M
YoY Change	159.52%	6.55%
Cash & Equivalents	$84.25M	$37.60M
Short-Term Investments	$13.33M
Other Short-Term Assets	$2.370M	$1.500M
YoY Change	58.0%	1.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$99.95M	$39.08M
YoY Change	155.78%	5.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$467.0K	$444.3K
YoY Change	5.11%	-20.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$498.0K	$600.0K
YoY Change	-17.0%	-21.4%
Total Long-Term Assets	$2.548M	$3.120M
YoY Change	-18.32%	-17.64%
TOTAL ASSETS
Total Short-Term Assets	$99.95M	$39.08M
Total Long-Term Assets	$2.548M	$3.120M
Total Assets	$102.5M	$42.20M
YoY Change	142.91%	3.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$715.0K	$1.305M
YoY Change	-45.21%	-55.88%
Accrued Expenses	$3.815M	$292.6K
YoY Change	1203.83%	-75.38%
Deferred Revenue	$2.468M	$793.0K
YoY Change	211.22%	11.33%
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$7.523M	$2.910M
YoY Change	158.57%	-51.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.999M	$3.600M
YoY Change	-44.47%	-28.61%
Total Long-Term Liabilities	$1.999M	$3.641M
YoY Change	-45.1%	-27.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.523M	$2.910M
Total Long-Term Liabilities	$1.999M	$3.641M
Total Liabilities	$9.522M	$6.551M
YoY Change	45.36%	-40.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$379.9M	-$340.3M
YoY Change	11.62%	11.62%
Common Stock	$27.00K	$12.00K
YoY Change	125.0%	-94.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.97M	$35.65M
YoY Change
Total Liabilities & Shareholders Equity	$102.5M	$42.20M
YoY Change	142.91%	3.67%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$12.96M	-$6.588M
YoY Change	96.75%	-62.32%
Depreciation, Depletion And Amortization	$37.00K	$30.00K
YoY Change	23.33%	-9.91%
Cash From Operating Activities	-$10.89M	-$6.190M
YoY Change	75.86%	-62.12%
INVESTING ACTIVITIES
Capital Expenditures	$61.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$7.725M
YoY Change
Cash From Investing Activities	-$7.786M	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	34.17M
YoY Change	-100.0%	-10330.54%
NET CHANGE
Cash From Operating Activities	-10.89M	-6.190M
Cash From Investing Activities	-7.786M	0.000
Cash From Financing Activities	0.000	34.17M
Net Change In Cash	-18.67M	27.98M
YoY Change	-166.73%	-267.55%
FREE CASH FLOW
Cash From Operating Activities	-$10.89M	-$6.190M
Capital Expenditures	$61.00K	$0.00
Free Cash Flow	-$10.95M	-$6.190M
YoY Change	76.85%	-62.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	Operating Expenses OperatingExpenses	14233000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14227000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6780000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240930#SublicenseAndOtherRevenueMember
CY2023Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240930#SublicenseAndOtherRevenueMember
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	VISTAGEN THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5093315
	dei	Entity Address Address Line1 EntityAddressAddressLine1	343 Allerton Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	577-3600
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	VTGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27843466	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84246000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119166000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13332000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2370000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1506000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	99948000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	120672000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	467000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	435000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1583000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1820000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	498000	usd
CY2024Q3	us-gaap	Assets Assets	102496000	usd
CY2024Q1	us-gaap	Assets Assets	123653000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	715000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3815000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2235000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2468000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	791000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	525000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	550000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7523000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5123000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	730000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2674000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1269000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1570000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	9522000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	9367000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27059629	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27029731	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	474441000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522	shares
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968000	usd
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-379908000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356214000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	92974000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	114286000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102496000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	183000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	278000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001411685
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240930#SublicenseAndOtherRevenueMember
CY2024Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240930#SublicenseAndOtherRevenueMember
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	726000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	476801000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123653000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	267000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	455000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	183000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	278000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	267000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	455000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10215000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3851000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17863000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8048000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4195000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3207000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8762000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6185000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	14410000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	7058000	usd
	us-gaap	Operating Expenses OperatingExpenses	26625000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26358000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13778000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1273000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	192000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2671000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	290000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12954000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6588000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23687000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13488000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12961000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6588000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23694000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13491000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	20000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	22000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12941000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6588000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23672000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13491000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.55
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30632347	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30632347	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10042530	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10042530	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30617970	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30617970	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8717050	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8717050	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12080000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	569000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1099000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6903000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6849000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	584000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34800000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6588000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	35645000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	114286000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1160000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	88000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	2000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-10733000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	104803000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1112000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12961000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	92974000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23694000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13491000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	63000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2272000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1153000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	237000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	215000	usd
	vtgn	Accretion On Marketable Securities AccretionOnMarketableSecurities	-159000	usd
	vtgn	Accretion On Marketable Securities AccretionOnMarketableSecurities	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	864000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-289000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-190000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-326000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-234000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-230000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-413000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	748000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1663000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21755000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14081000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	103000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5498000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	18648000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13253000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36033000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	88000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	4000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	986000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35051000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34920000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20970000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	119166000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16638000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	84246000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37608000	usd
	vtgn	Insurance Premiums Settled By Issuing Note Payable InsurancePremiumsSettledByIssuingNotePayable	0	usd
	vtgn	Insurance Premiums Settled By Issuing Note Payable InsurancePremiumsSettledByIssuingNotePayable	880000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, but are not limited to, those relating to stock-based compensation, revenue recognition, research and development expenses, determination of right-of-use assets under lease transactions and related lease obligations, and the assumptions used to value warrants. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></div>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-379900000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	97600000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	97578000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	119166000	usd
CY2024Q3	vtgn	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	13310000	usd
CY2024Q3	vtgn	Debt Securities Available For Sale And Cash And Cash Equivalents Accumulated Gross Unrealized Gain DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedGain	22000	usd
CY2024Q3	vtgn	Debt Securities Available For Sale And Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	vtgn	Debt Securities Available For Sale And Cash And Cash Equivalents DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents	13332000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	vtgn	Warrants Exercisable Percentage Of Common Shares Outstanding Minimum Benchmark WarrantsExercisablePercentageOfCommonSharesOutstandingMinimumBenchmark	0.0999
CY2023Q4	vtgn	Warrants Exercisable Percentage Of Common Shares Outstanding Maximum Benchmark WarrantsExercisablePercentageOfCommonSharesOutstandingMaximumBenchmark	0.1999
CY2023Q4	vtgn	Warrant Percentage Increase Or Decrease Notice Period WarrantPercentageIncreaseOrDecreaseNoticePeriod	P61D
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P60D
	vtgn	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	6.24
CY2024Q3	vtgn	Class Of Warrant Or Right Outstanding Warrants Subject To Anti Dilution Protection Feature ClassOfWarrantOrRightOutstandingWarrantsSubjectToAntiDilutionProtectionFeature	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	815357	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.07
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	165000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2315700	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.65
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	18742	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.18
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3112315	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	979168	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3112315	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	13000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1112000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	584000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2272000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1153000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.46
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2000000.0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1200000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7900000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23717109	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	770240	shares
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	200000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	300000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	300000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	500000	usd
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001411685-24-000048-index-headers.html	Edgar Link	pending
0001411685-24-000048-index.html	Edgar Link	pending
0001411685-24-000048.txt	Edgar Link	pending
0001411685-24-000048-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtgn-20230930xexx32.htm	Edgar Link	pending
vtgn-20240930.htm	Edgar Link	pending
vtgn-20240930.xsd	Edgar Link	pending
vtgn-20240930xexx311.htm	Edgar Link	pending
vtgn-20240930xexx312.htm	Edgar Link	pending
vtgn-20240930_def.xml	Edgar Link	unprocessable
vtgn-20240930_lab.xml	Edgar Link	unprocessable
vtgn-20240930_pre.xml	Edgar Link	unprocessable
vtgn-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
vtgn-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q4 Form 10-Q Financial Statement

#000141168524000048 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q4 Form 10-Q Financial Statement

#000141168524000048 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn